Form 8-K Receptos, Inc. For: Mar 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Receptos (RCPT) Misses Q4 EPS by 13c
March 3, 2015 4:21 PM ESTReceptos (NASDAQ: RCPT) reported Q4 EPS of ($1.32), $0.13 worse than the analyst estimate of ($1.19).
Development Program Updates
Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (RMS)
After reporting positive results in the Phase 2 portion of the RADIANCE trial of ozanimod in RMS, Receptos initiated the second Phase 3 trial of ozanimod in RMS, called SUNBEAM. Similar to the RADIANCE Phase 3 trial, the SUNBEAM trial is a randomized, double-blind study designed to compare 0.5 mg and 1.0 mg of ozanimod against interferon beta-1a (Avonex®) in approximately 1,200 patients with RMS. The primary objectives of the... More